Skip banner and top navigation
National Heart, Lung, and Blood Institute Home Page Link to the National Institutes of Health Link to the Department of Health and Human Services
  Home » Information for Researchers » NHLBI Research and Policy Listserv

NHLBI Research and Policy Update
Number 9   September 2004
This electronic distribution list will provide updates from the NHLBI Web Site for the research community. The Updates will be sent as needed, but no more than once a week.

bulletFunding Updates

RFA-HL-04-036: Causes and Mechanisms of COPD Exacerbations
 Receipt Dates: Letter of Intent, December 13, 2004

 Application, January 11, 2005

RFA-HL-04-022: Bioengineering Approaches to Energy Balance and Obesity
 Receipt Dates: Letter of Intent, January 17, 2005
 Application, February 16, 2005

PA-04-156: Bioengineering Approaches to Energy Balance and Obesity (SBIR/STTR)

For additional initiatives, please visit the following Web page:
NHLBI Grants and Contracts page

bulletPolicy Updates

Policy on Human Subjects Research Data and Safety Monitoring Plans (policy update and title change)

For additional policy documents, please visit Funding / Award Policy section on the following Web page:
Funding, Training, and Policies

bulletTraining Updates

No updates or new training documents have been issued.

For more information on training and career development programs, please visit the following Web page:
Training and Career Development


List of upcoming meetings

National Heart, Lung, and Blood Advisory Council Meeting, October 21, 2004

AHA/NHLBI 3rd Annual Workshop on Cardiovascular Interventional MRI, November 8, 2004

For more information on upcoming meetings, please visit the following Web page:
Announcements of NHLBI Meetings, Conferences, and Events

Reports of past meetings

National Heart, Lung, and Blood Advisory Council, September Meeting Summary, September 2004

Reporting Genetic Results in Research Studies, NHLBI Working Group Meeting Summary, July 2004

RNAi for Gene Transfer Approaches to Heart, Lung, and Blood Diseases, NHLBI Working Group, July 2004

Determining the Role of Subclinical Disease Testing in Patients at Intermediate Risk, NHLBI Working Group Report, July 2004

Future Clinical Research Directions on Omega-3 Fatty Acids and Cardiovascular Disease, 2004 Working Group Summary, June 2004

National Heart, Lung, and Blood Advisory Council Meeting Minutes, May 2004

Hypertension Treatment Trials: Future Directions, 2003 NHLBI Workshop, Executive Summary, September 2003

Future Directions in Sarcoidosis Research, NHLBI Working Group Summary (Published in Am J Respir Crit Care Med Vol 170. pp 567–571, 2004), August 2002

For more information on past meetings, please visit the following Web page:
Workshop and Meeting Summaries, and Other Scientific Reports

bulletPress Releases

Cholesterol Guidelines: The Strength of the Science Base and the Integrity of the Development Process—Statement from Barbara Alving, M.D., Acting Director, NHLBI, September 24, 2004

For additional Press Releases, please visit the following Web page:
Current Press Releases

bulletSelected NHLBI Vacancies

Technical Writer-Editor

Technical Writer-Editor

Note: There are often changes and additions to this list, for the most current information, please visit the NHLBI Jobs Opportunities page

bulletOther Items of Interest

FYI from the NHLBI: Public Interest News, September 2004

Legislative Update, NHLBI Express, September 2004

JNC 7 (Hypertension) Full Report--printed version

The Patient Registry for Primary Pulmonary Hypertension (PPH Registry)
The registry was established to evaluate the natural history, etiology, pathogenesis and treatment of primary pulmonary hypertension. Specific aims included the characterization of the demographic, medical history, family history, physical and laboratory findings of patients at time of diagnosis, and to characterize the survival duration of patients by traits evaluated at diagnosis and by medical interventions. There were 1.7 females for each male in the registry, and females tended to present with more severe symptoms. The mean time from onset of symptoms to diagnosis was 2 years. Right ventricular hypertrophy was found in 87% of patients and right atrial pressure was elevated in 72% of patients. The estimated median survival was 2.8 years with single year survival rates of: 1 year, 68%; 3 years, 48%; and 5 years, 34%. (Ann Intern Med, 1987; 107:216-23, Ann Intern Med, 1991; 115:343-49).

bulletAn Archive of the current and past issues is available on the NHLBI Web site.

Two ways to unsubscribe:
  1. Send an e-mail message to: LISTSERV@LIST.NIH.GOV
    and, in the text of your message (not the subject line), write (or copy/paste):

  2. Use the List Web Page
    A) select this link
    B) Enter your e-mail address as it appears in the To: field of the list,
    C) Enter your full name, and
    D) Select the button, Leave the list.